Live Breaking News & Updates on Nasdaq Traded Company

Stay updated with breaking news from Nasdaq traded company. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Orchestra BioMed Debuts as Nasdaq-traded Company with Lead Programs Targeting Hypertension and Artery Disease and Novel Partnership-Enabled Business M

Orchestra BioMed Debuts as Nasdaq-traded Company with Lead Programs Targeting Hypertension and Artery Disease and Novel Partnership-Enabled Business Model Business combination with Health Sciences Acquisitions Corporation 2, a special purpose acquisition company sponsored by an affiliate of RTW Investments, LP,. ....

David Hochman , Sirolimus Angioinfusion , Broderick Wong , Novel Partnership , Orchestra Biomed Debuts As Company , Orchestra Biomed Inc , Orchestra Biomed Holdings Inc , Health Sciences Acquisitions Corporation , Orchestra Biomed Debuts , Nasdaq Traded Company , Lead Programs Targeting Hypertension , Artery Disease , Novel Partnership Enabled Business , Backbeat Cardiac Neuromodulation Therapy , Biomed Holdings , Nasdaq Global Market , Orchestra Biomed , Chief Executive Officer , Co Founder David Hochman , Perceptive Advisors , Sternaegis Ventures , Managing Partner , Chief Investment Officer ,

Sigyn Therapeutics (SIGY) CEO Note: Overcoming the Limitations of Previous Cytokine Storm Treatment Strategies

Sigyn Therapeutics (SIGY) CEO Note: Overcoming the Limitations of Previous Cytokine Storm Treatment Strategies
SAN DIEGO, Jan. 12, 2021 via
NewMediaWire Sigyn Therapeutics, Inc. (OTCMarkets: SIGY), today released the following note authored by its Chairman and CEO, Jim Joyce.
Dear Current and Candidate Shareholders,
We created Sigyn Therapy to address a significant unmet need in global health; the treatment of life-threatening inflammatory conditions that are precipitated by Cytokine Storm Syndrome (the Cytokine Storm). An annual market opportunity that exceeds $20 billion.
Based on our cumulative experience in developing first-in-industry medical technologies, we designed Sigyn Therapy to overcome the limitations of previous strategies to treat cytokine storm related conditions, yet still optimize patient safety and support widespread deployment. ....

United States , San Diego , Jim Joyce , Contact Sigyn Therapeutics Inc , Reign Resources Corporation Quarterly Report On Form , Sigyn Therapeutics Inc , Drug Administration , Sigyn Therapeutics , Candidate Shareholders , Sigyn Therapy , Cytokine Storm Syndrome , Cytokine Storm , Investigational Device Exemption , United States Food , Aethlon Medical , Nasdaq Traded Company , California United , Private Securities Litigation Reform Act , Reign Resources Corporation Quarterly Report , ஒன்றுபட்டது மாநிலங்களில் , சான் டியாகோ , ஜிம் மகிழ்ச்சி , ஆட்சி வளங்கள் நிறுவனம் காலாண்டு அறிக்கை ஆன் வடிவம் , வேட்பாளர் பங்குதாரர்கள் , ஒன்றுபட்டது மாநிலங்களில் உணவு , நாஸ்டாக் வர்த்தகம் செய்யப்பட்டது நிறுவனம் ,